Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There have been many reports on the Event-Related Potentials (ERPs) abnormalities, especially P300 amplitudes reduction, in schizophrenic patients. However the relationships between P300 abnormalities and schizophrenic subtypes have not been clarified. This study aims to investigate the relationships in a relatively large number of drug free schizophrenics. Seventy three unmedicated schizophrenic patients (45 males, 28 females) who met the DSM-III-R criteria for schizophrenia were tested. Twenty seven of the schizophrenics were paranoid type according to the DSM-III-R, 23 were undifferentiated, 19 were disorganized, 2 catatonic and 2 residual. Seventy three healthy controls were age and gender matched to the patient group. All the ERPs were recorded during auditory odd ball task. Stimuli consists of 2 kHz and 1 kHz tone bursts, and the respective probabilities of the rare and frequent stimuli were 0.2 and 0.8. They were presented random order. The duration of each stimulus was 90 msec with rise and fall times of 10 msec, and the intensity was approximately 70 dB SPL for all the stimuli. The inter-stimulus intervals were 1.7 +/- 0.1 seconds. The subjects were instructed to count the numbers of rare tones. The scalp EEGs were recorded from Ag-AgCl electrodes at 16 sites that referred to linked earlobes. P300 amplitudes reduction [F (1,144) = 39.33, p < 0.001] and P300 latencies prolongation [F (1,144) = 12.41, p < 0.001] were found in schizophrenic group as a whole. Lower amplitude of P300 was observed at both right and left temporal sites in the subjects with undifferentiated type and disorganized type. Although in the subjects with paranoid type, the reduction was recognized at left temporal region, reduced amplitude was not seen at right temporal site. While no relationships between P300 amplitudes, the score of BPRS and SAPS were detected, in the patient with paranoid type, significant negative correlation between P300 amplitudes and SANS total scores was observed (r = -0.425, p = 0.03) at Pz site. These results were discussed with respect to cognitive impairment of schizophrenia.
 ...
PMID:[Cognitive impairment in schizophrenic patients on event-related potentials component P300]. 837 57

The aim of this study was to examine whether specific forms of formal thought disorder distinguish schizophrenia from schizophreniform and schizoaffective psychoses. The sample was composed of 82 consecutively admitted patients with schizophrenic symptoms. Of these, 28 had a diagnosis of schizophrenia by RDC and DSM-IIIR criteria, 28 a diagnosis of schizophrenia by RDC but not DSM-IIIR (consequently they were labeled schizophreniform), and 26 a diagnosis of manic schizoaffective disorder by RDC criteria. They were assessed by a semi-structured interview for schizophrenia, by scales for positive and negative symptoms (SAPS and SANS) and by prognostic indicators. The assessment of thought disorder was carried out by using the Thought, Language and Communication scale (TLC). The schizophrenic patients showed higher global scores on formal thought disorder, and some of its subtypes were 'most specific' to schizophrenia (poverty of speech, poverty of content of speech, illogicality, tangentiality and perseveration). Schizophrenics had more loose associations than schizophreniforms. Manic schizoaffectives had higher scores on positive versus negative formal thought disorder than schizophreniforms. We suggested that the assessment of disordered thinking by the TLC may facilitate the differential diagnosis of psychotic disorders during the acute phase of the illness.
 ...
PMID:Does formal thought disorder differ among patients with schizophrenic, schizophreniform and manic schizoaffective disorders? 839 47

The SFII (Short-Form Impairment Index, Horton and cols, 1986) was used to assess cognitive impairment in patients with DSM-III-R diagnosis of schizophrenia and its relationship to the positive and negative schizophrenic symptoms was studied. Two samples of DSM-III-R schizophrenic patients were studied. The first sample was composed of 30 consecutively inpatients admitted by recrudescence of their symptoms. The second was composed of 19 patients that were attending to a Day Psychiatric Hospital by recrudescence of their symptoms or by socio-familiar dysfunctions. The SFII included three subtest: the "Trail Making" Form B, and cubes and digit symbol from the WAIS, that were converted to typical scores adjusted to age (Reitan, 1973). The positive and negative schizophrenic symptoms were assessed by the Andreasen scales (SAPS y SANS). No differences in epidemiological variables were found between both samples. Higher cognitive impairment (lower SFII) and higher negative symptoms were significantly correlated in both samples. This result suggests that the SFII could be a good marker of cognitive functioning in schizophrenic patients in postacute samples and also in mixed schizophrenic patients (acute and defectual population). The SFII presented some limitations in our young samples derived from their age-corrected values.
 ...
PMID:[The Short-Form impairment index (SFII) in schizophrenic patients]. 847 20

This paper examines structural brain abnormalities, as evaluated by the CT scan, in first episodes of schizophrenia and their association with sociodemographic, diagnostic and clinical variables. The investigation included all patients with a first episode of schizophrenia who, over a 2-year period, made contact with any of the public mental health services of the Autonomous Region of Cantabria in Northern Spain. Diagnostic and clinical characteristics were evaluated through the use of the Spanish version of the Present State Examination (PSE-9) and the Scales for the Assessment of Positive and Negative Symptoms (SANS and SAPS respectively). The study demonstrated the presence of structural brain abnormalities in this sample of first episode schizophrenics. These abnormalities were mainly expressed in the presence of larger VBR for schizophrenic patients than in the controls, these findings being more marked in women than in men. We failed to reveal, however, any evidence of an association of these brain abnormalities with diagnostic or clinical characteristics.
 ...
PMID:Structural abnormalities of the brain in schizophrenia: sex differences in the Cantabria First Episode of Schizophrenia Study. 863 54

103 patients were admitted for the first time to the psychiatric hospital (Institute of Psychiatry and Neurology in Warsaw) between 1976-1983 and received a research diagnosis of schizophrenia (in accordance with the ICD-9 criteria). The course and clinical pattern of the illness were analyzed at a follow-up in 65 patients--rehospitalized in the 5th year from their first admission. As regards the clinical pattern analysis, it was focused mostly on positive and negative symptoms occurrence, as assessed using the Andreasen Scales (SANS, SAPS). The data obtained from the case reports were statistically tested and the results were presented in the tables according to the research questions. The frequency of occurrence of at least one negative symptom was found to be high in the group under study (in 72% of patients during the first hospitalization and in 83% at the five-years' follow-up). The increment in the frequency of occurrence pertained also to all groups of negative symptoms, which is concordant with many authors, results.
 ...
PMID:[The frequency of occurrence of negative symptoms at the early stage of schizophrenic psychosis]. 872 37

Forty-eight schizophrenic outpatients treated with flexible doses of haloperidol decanoate were followed up in a naturalistic fashion for 3 years with periodic monitoring of clinical symptoms, side effects and haloperidol plasma concentrations. There was no relationship between plasma level and clinical response, however categorical data analysis showed that patients with plasma levels over 4 ng/ml had a significantly reduced relapse rate compared with patients with plasma levels below this plasma 'threshold' level. This effect could be observed during the first, second as well as third year of treatment. The relapse rate did not change significantly in relation to time (during years 1, 2, 3), when patients with haloperidol plasma levels below and equal to or over 4 ng/ml were considered separately. In patients with haloperidol equal to or over 4 ng/ml, the variability (measured as coefficient of variation %) in the total scores of SAPS and SANS was lower, indicating a better clinical stability. These data are in fairly good agreement with other literature findings showing that an indiscriminate dose reduction strategy during long-term treatment of schizophrenic disorders with haloperidol decanoate should be discouraged, since it leads to an increase in the relapse rate. Before deciding about a dose reduction, clinicians should take into careful consideration some clinically relevant variables (i.e. frequency of previous relapses, severity of symptoms, iatrogenic depression, risk for development of extrapyramidal side effects) for each patient. A better clinical stability during treatment with haloperidol decanoate can be obtained when plasma 'threshold' levels for response are reached.
 ...
PMID:Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. 877 59

This study was a preliminary open clinical trial aimed at exploring the hypothesis that estrogen may provide protection against schizophrenia in women. Eleven women with acute psychotic symptoms, as scored on the BPRS, SAPS and SANS, had 0.02 mg estradiol added to neuroleptic treatment for eight weeks. Their response was compared to seven women with similar symptom severity receiving neuroleptic treatment alone. Both groups had baseline hormonal assays of estrogen, progesterone, LH and FSH and underwent regular psychopathology ratings during the eight weeks. The group receiving the estradiol adjunct showed more rapid improvement in psychotic symptoms compared with the group receiving neuroleptics only. This difference was not sustained for the entirety of the trial. Both groups reached similar levels of recovery by the eighth week. These results suggest that estradiol may have antipsychotic properties and/or act as a catalyst for neuroleptic responsiveness in women with schizophrenia.
 ...
PMID:A clinical trial of the effects of estrogen in acutely psychotic women. 882 50

This paper examines the association of clinical and sociodemographic factors, including age and sex, with the diagnostic characteristics of first episodes of schizophrenia. The study included all patients with a first episode of schizophrenia who made contact with any of the public mental health services of the Autonomous Region of Cantabria in Northern Spain over a period of 2 years. Diagnostic characteristics were determined using the Spanish version of the Present State Examination (PSE-9), and the Scales for the Assessment of Positive and Negative Symptoms (SAPS and SANS, respectively). The study confirms that the onset of schizophrenia tends to occur earlier in men than in women. However, neither sex nor age of onset were found to be associated with the clinical and psychopathological characteristics of the patients as established by the PSE-CATEGO-ID system. Furthermore, no other factors were found to be associated with these diagnostic characteristics. Being female, having a family history of mental illness, and a poor premorbid adjustment were found to predict negative symptoms as defined by SANS/SAPS scales.
 ...
PMID:Sociodemographic and clinical variables as predictors of the diagnostic characteristics of first episodes of schizophrenia. 889 Oct 79

The aims of this study were (1) to test the hypothesis that the clinical profiles of deficit, nondeficit, and negative symptom patients are difficult to distinguish during episodes of acute psychotic decompensation; and (2) to compare these groups of schizophrenic patients in terms of sociodemographic and anamnestic variables. Patients admitted for acute psychotic decompensation were retrospectively diagnosed as having deficit (N = 18) or nondeficit (N = 40) forms of schizophrenia and their symptom profiles were evaluated cross-sectionally by using various rating scales (SAPS, SANS, and PANSS). As a whole, nondeficit patients were clearly differentiated from deficit patients by lower severity of negative symptoms. However, the subgroup (N = 24) of nondeficit patients with prominent negative symptoms that were secondary and/or nonenduring showed a symptom profile largely overlapping with that of deficit patients. Attentional impairment was the only measure distinguishing deficit and negative symptom patients. As for trait variables, deficit patients had lower education than the other two groups and, among male subjects, there was a higher percentage of left-handers in the deficit group than in the negative symptom subgroup. These results confirm the importance of diagnosing the deficit syndrome during periods of clinical stability in order to avoid the risk of misclassifying negative symptom patients into the deficit group.
 ...
PMID:Patients with deficit, nondeficit, and negative symptom schizophrenia: do they differ during episodes of acute psychotic decompensation? 913 95

We assessed the comparative interrater reliability of the SANS/SAPS and PANSS as measures of symptomatology in schizophrenia and also examined the interrelationship between scores on these instruments. Two experienced raters used these Scales to assess positive and negative symptoms in a group of 85 patients with a DSM III-R diagnosis of schizophrenia. Ratings were based on structured clinical interviews, review of case notes and consultation with staff familiar with the patients. Comparable levels of interrater reliability were found for each system of measuring symptomatology, but levels of interrater reliability were on the whole lower than have been reported in the past. There were high correlations between overall indices of positive and negative symptomatology derived from the two measurement systems.
 ...
PMID:A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. 914 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>